Eli Lilly shares moved higher after the company reported positive Phase 3 results for Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Lilly said the BRUIN CLL-322 trial met its primary endpoint, with the added regimen lowering the risk of progression or death compared with venetoclax plus rituximab alone.
The company reported that the independent review committee assessed progression-free survival and that adding pirtobrutinib to the two-year venetoclax-and-rituximab backbone reduced the risk of disease progression or death by 45%. Overall survival data were not yet mature, while a secondary endpoint measuring time to next treatment also consistently favored the combination.
Key takeaways
- Price move: Eli Lilly shares rose following the Phase 3 BRUIN CLL-322 readout.
- Catalyst: Jaypirca plus venetoclax and rituximab met the primary endpoint of independent review committee–assessed progression-free survival.
- Key result: The company said the combination reduced the risk of progression or death by 45% versus venetoclax and rituximab alone.
- Implication: The trial supports pirtobrutinib’s potential to improve outcomes in a treatment setting that reflects current use of covalent BTK inhibitors.
- What’s missing: Overall survival superiority testing is planned later, with results not yet mature.
What drove the move
According to Lilly, the Phase 3 BRUIN CLL-322 study evaluated pirtobrutinib—a non-covalent BTK inhibitor—combined with venetoclax and rituximab versus the same venetoclax-and-rituximab regimen without pirtobrutinib. The primary endpoint was progression-free survival assessed by an independent review committee.
Lilly said the trial met that endpoint, with the pirtobrutinib-containing regimen cutting the risk of disease progression or death by 45%. The company also reported that time to next treatment, another secondary endpoint, consistently favored the combination therapy.
Beyond efficacy, the company pointed to a safety profile that aligns with what’s expected from each medicine individually. Lilly said little additive toxicity was observed when pirtobrutinib was added to venetoclax and rituximab, supporting tolerability in the combination setting.
Market reaction and what investors will focus on
The market response to trial readouts in oncology often centers on whether a study improves clinically meaningful outcomes beyond disease control, particularly progression-free survival, and whether safety remains manageable in combination regimens. In this case, Lilly’s update delivered positive evidence on disease progression and time to treatment change, two factors that can influence how physicians sequence therapy.
However, investors typically look for eventual confirmation through overall survival results. Lilly said overall survival was a key secondary endpoint but was not yet mature at the time of this analysis, with final testing of OS superiority planned for a future date. That timeline uncertainty can shape expectations for near-term sentiment, particularly if traders and analysts weigh how much weight to place on progression-free survival before survival outcomes are reported.
Why the trial design matters in today’s CLL landscape
Lilly described BRUIN CLL-322 as the first Phase 3 study to show superiority over a venetoclax-containing control arm in CLL. The company also highlighted that many patients in the trial previously received a covalent BTK inhibitor, aligning with current practice patterns where covalent BTK inhibitors are commonly used earlier in disease.
This context is significant because pirtobrutinib is positioned as a non-covalent BTK inhibitor, potentially offering an option for patients whose disease has progressed despite prior BTK therapy or who may not benefit from covalent approaches. By reflecting real-world treatment history, the data may be more readily interpreted for future adoption if regulators and clinicians evaluate it against existing standards.
Bigger picture: implications for combination therapy
According to Lilly, the regimen demonstrated consistent benefit without meaningful incremental toxicity, an important consideration when integrating new targeted therapies into multi-drug standards. The combination of pirtobrutinib with venetoclax and rituximab aims to build on the established venetoclax-plus-rituximab backbone while adding BTK inhibition through a mechanism designed to be distinct from covalent inhibitors.
With overall survival still pending and additional testing planned, the immediate takeaway is efficacy on progression-focused endpoints alongside an acceptable safety signal. The next milestone for the market will be what happens when the company completes final OS analyses and how the data compare with other approaches in relapsed or refractory CLL/SLL.
What to watch next includes the timing of final overall survival superiority results for BRUIN CLL-322 and any follow-on updates from Lilly regarding regulatory timelines and broader product development. Investors will also monitor upcoming oncology and company disclosures as the market assesses how strongly progression-free survival benefits translate into long-term clinical outcomes.
